Escitalopram
- Generic Name
- Escitalopram
- Brand Names
- Cipralex, Lexapro
- Drug Type
- Small Molecule
- Chemical Formula
- C20H21FN2O
- CAS Number
- 128196-01-0
- Unique Ingredient Identifier
- 4O4S742ANY
- Background
Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic citalopram. It is used to restore serotonergic function in the treatment of depression and anxiety. Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible for the vast majority of citalopram’s clinical activity, with...
- Indication
Escitalopram is indicated for the acute and maintenance treatment of major depressive disorder (MDD) in adults and pediatric patients 12 years old and older and for the acute treatment of generalized anxiety disorder (GAD) in adults and pediatric patients 7 years old and older. It is additionally indicated for symptomatic relief of obsessive-compulsive disor...
- Associated Conditions
- Anxiety, Generalized Anxiety Disorder, Major Depressive Disorder (MDD), Obsessive Compulsive Disorder (OCD)
- Associated Therapies
- -
Efficacy of Seroquel SR in Combination With an Antidepressant in Treatment of Major Depressive Disorder
- Conditions
- First Posted Date
- 2006-07-12
- Last Posted Date
- 2008-12-22
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 450
- Registration Number
- NCT00351169
- Locations
- 🇪🇸
Research Site, Zamora, Spain
Tolerability and Efficacy of High Dose Escitalopram for the Treatment of Obsessive-Compulsive Disorder (OCD)
- Conditions
- First Posted Date
- 2006-03-22
- Last Posted Date
- 2006-07-26
- Lead Sponsor
- Abarbanel Mental Health Center
- Target Recruit Count
- 100
- Registration Number
- NCT00305500
- Locations
- 🇮🇱
Abarbanel MHC, Bat-Yam, Israel
PTSD Prevention Using Escitalopram
- Conditions
- Interventions
- First Posted Date
- 2006-03-08
- Last Posted Date
- 2013-12-31
- Lead Sponsor
- Sheba Medical Center
- Target Recruit Count
- 450
- Registration Number
- NCT00300313
- Locations
- 🇮🇱
Hadassa Medical Center, Jerusalem, Israel
🇮🇱Barzilai Medical Center, Ashkelon, Israel
🇮🇱Soroka Medical Center, Beer-Sheva, Israel
Memory Functioning and Antidepressant Treatment
- Conditions
- First Posted Date
- 2006-02-27
- Last Posted Date
- 2009-02-17
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 60
- Registration Number
- NCT00296933
- Locations
- 🇨🇦
University Health Network, Toronto, Ontario, Canada
Treatment of Depression Following Multiple Brain Tests
- Conditions
- Interventions
- First Posted Date
- 2006-02-27
- Last Posted Date
- 2012-04-27
- Lead Sponsor
- New York State Psychiatric Institute
- Target Recruit Count
- 28
- Registration Number
- NCT00296777
- Locations
- 🇺🇸
Depression Evaluation Service - New York State Psychiatric Institute, New York, New York, United States
Mineralocorticoid Receptor in the Treatment of Severe Depression
- Conditions
- First Posted Date
- 2006-02-23
- Last Posted Date
- 2017-05-30
- Lead Sponsor
- Universitätsklinikum Hamburg-Eppendorf
- Target Recruit Count
- 65
- Registration Number
- NCT00295347
- Locations
- 🇩🇪
University Hospital Hamburg-Eppendorf, Hamburg, Germany
Treatment Resistant Bipolar Depression
- First Posted Date
- 2006-01-04
- Last Posted Date
- 2015-12-16
- Lead Sponsor
- Queen's University
- Target Recruit Count
- 1
- Registration Number
- NCT00272025
- Locations
- 🇨🇦
Providence Care, Mental Health Services, Kingston, Ontario, Canada
DBT and Escitalopram in Borderline Personality Disorder
- Conditions
- First Posted Date
- 2005-11-21
- Last Posted Date
- 2005-11-21
- Lead Sponsor
- Bronx VA Medical Center
- Registration Number
- NCT00255554
- Locations
- 🇺🇸
Bronx VA Medical Center, Bronx, New York, United States
Functional Dyspepsia Treatment Trial
- Conditions
- Interventions
- First Posted Date
- 2005-11-04
- Last Posted Date
- 2014-07-25
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 292
- Registration Number
- NCT00248651
- Locations
- 🇺🇸
Northwestern University Chicago, Chicago, Illinois, United States
🇺🇸Baylor College of Medicine, Houston, Texas, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
MOTIV Study- Effect of Antidepressive Treatment by Escitalopram in Patients Undergoing Coronary Artery Bypass Grafting
- First Posted Date
- 2005-10-24
- Last Posted Date
- 2012-03-19
- Lead Sponsor
- Hopital Jean Minjoz
- Target Recruit Count
- 368
- Registration Number
- NCT00243477
- Locations
- 🇫🇷
Sidney Chocron, Besançon, Doubs, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.